WDN/TMH:dv 12/31/03 CLA/P015700US
PATENT

Attorney Reference Number 5585-59112
Application Number 09/868,605

Listing of Claims

1. (Previously presented) A method of improving tolerance to a xenograft comprising: immunising a mammal with an immunogen comprising at least one T-cell epitope and at least one porcine polypeptide B-cell epitope, wherein said B-cell epitope is capable of mediating rejection of said xenograft.

2. (Amended) A method according to Claim 1, wherein said B-cell epitope is a peptide derived from ~~at least one~~ a porcine CD86 polypeptide ~~selected from the group of CD40, CD80, CD86 and VCAM~~.

3-4. (Cancelled).

5. (Amended) A method according to Claim ~~1~~2, wherein said peptide is selected from at least one peptide represented in Figure 26.

6. (Previously presented) A method according to Claim 1, wherein said T-cell epitope comprises a tetanus toxoid polypeptide.

7. (Previously presented) A composition comprising an immunogen characterised in that said immunogen comprises at least one B-cell epitope and at least one T-cell epitope wherein said B-cell epitope comprises a porcine epitope involved in mediating xenograft rejection.

8. (Previously presented) A composition according to Claim 7, wherein said porcine epitope comprises a porcine polypeptide expressed by vascular endothelial cells of said xenograft.

9. (Amended) A composition according to Claim 7, wherein said B-cell epitope is derived from ~~selected from the group of CD40,~~ CD86, ~~CD80 and VCAM~~.

10. (Cancelled)

11. (Cancelled)

12. (Previously presented) A composition according to Claim 9, wherein said B-cell epitope comprises at least one peptide as represented in Figure 26.

13. (Previously presented) A composition according to Claim 9, wherein said B-cell epitope comprises an extracellular domain of CD86.

14. (Previously presented) A composition according to Claim 7, wherein said T-cell epitope comprises a tetanus toxoid epitope.

15. (Previously presented) A composition according to Claim 7, wherein said composition further comprises a carrier capable of enhancing the immune response to said immunogen.

16-23. (Cancelled).

24. (Previously presented) The method Claim 1, wherein said B-cell epitope has less than 75% sequence identity to a corresponding region of an equivalent human polypeptide.

25. (Amended) The ~~method~~ composition of Claim 7, wherein said B-cell epitope has less than 75% sequence identity to a corresponding region of an equivalent human polypeptide.

26. (Cancelled).

27. (New) The method according to Claim 5, wherein said peptide comprises at least nine contiguous amino acids from SEQ ID NO: 14.

28. (New) The composition according to Claim 12, wherein said peptide comprises at least nine contiguous amino acids from SEQ ID NO: 14.